Tess De Bruyne

Dr. Tess De Bruyne

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2002 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
KCK Cimanga
K Cimanga
KKK Kambu
K Kambu
LTL Tona
L Tona
SAS Apers
S Apers
TBTess De Bruyne
Tess De Bruyne
AVA.J Vlietinck
A.J Vlietinck

1 May 2004 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PCPaul Cos
Paul Cos
TBTess De Bruyne
Tess De Bruyne
NHN. Hermans
N. Hermans
SAS. Apers
S. Apers
DBD. Berghe
D. Berghe
AVA. Vlietinck
A. Vlietinck
Polyphenolic compounds are widely distributed in higher plants and are an integral part of the human diet. Recent interest in these substances has been stimulated by their potential health benefits, which are believed to arise mainly from their antioxidant activity. In the past years, the antioxidant activity of flavonoids has been studied in detail. An important but often overlooked group of polyphenols is that of the proanthocyanidins. Therefore, the present review is focused mainly on the antioxidant activity of proanthocyanidins and its relevancy in vivo. The three most important mechanisms of their antioxidant action will be discussed, i.e. free radical scavenging activity, chelation of transition metals, and inhibition of enzymes. In addition, the protective role of proanthocyanidins against lipid peroxidation and peroxynitrite, as well as their antimicrobial properties will be discussed. To study the in vivo relevancy of the proanthocyanidin activities, the knowledge of their pharmacokinetic parameters is crucial. Although bioavailability and metabolism data on polyphenols in general and proanthocyanidins in particular are still largely unavailable, the first reports indicate that at least monomers and smaller oligomeric procyanidins are absorbed. There is also considerable scientific and public interest in the important role that antioxidants may play in health care, e.g. by acting as cancer chemopreventive and antiinflammatory agents and by reducing risk of cardiovascular mortality. Each of these aspects will be discussed, with special attention to the role of proanthocyanidins on apoptosis, gene expression and transcription factors, such as NF-kappa B.

1 March 1998 in Planta Medica
Verified
Journal Article
Closed access
PDF file
AVA. Vlietinck
A. Vlietinck
TBTess De Bruyne
Tess De Bruyne
SAS. Apers
S. Apers
LPLuc Pieters
Luc Pieters
Many compounds of plant origin have been identified that inhibit different stages in the replication cycle of human immunodeficiency virus (HIV): 1) virus adsorption: chromone alkaloids (schumannificine), isoquinoline alkaloids (michellamines), sulphated polysaccharides and polyphenolics, flavonoids, coumarins (glycocoumarin, licopyranocoumarin) phenolics (caffeic acid derivatives, galloyl acid derivatives, catechinic acid derivatives), tannins and triterpenes (glycyrrhizin and analogues, soyasaponin and analogues); 2) virus-cell fusion: lectins (mannose- and N-acetylglucosamine-specific) and triterpenes (betulinic acid and analogues); 3) reverse transcription: alkaloids (benzophenanthridines, protoberberines, isoquinolines, quinolines), coumarins (calanolides and analogues), flavonoids, phloroglucinols, lactones (protolichesterinic acid), tannins, iridoids (fulvoplumierin) and triterpenes; 4) integration: coumarins (3-substituted-4-hydroxycoumarins), depsidones, O-caffeoyl derivatives, lignans (arctigenin and analogues) and phenolics (curcumin); 5) translation: single chain ribosome inactivating proteins (SCRIP's); 6) proteolytic cleavage (protease inhibition): saponins (ursolic and maslinic acids), xanthones (mangostin and analogues) and coumarins; 7) glycosylation: alkaloids including indolizidines (castanospermine and analogues), piperidines (1-deoxynojirimicin and analogues) and pyrrolizidines (australine and analogues); 8) assembly/release: naphthodianthrones (hypericin and pseudohypericin), photosensitisers (terthiophenes and furoisocoumarins) and phospholipids. The target of action of several anti-HIV substances including alkaloids (O-demethyl-buchenavianine, papaverine), polysaccharides (acemannan), lignans (intheriotherins, schisantherin), phenolics (gossypol, lignins, catechol dimers such as peltatols, naphthoquinones such as conocurvone) and saponins (celasdin B, Gleditsia and Gymnocladus saponins), has not been elucidated or does not fit in the proposed scheme. Only a very few of these plant-derived anti-HIV products have been used in a limited number of patients suffering from AIDS viz. glycyrrhizin, papaverine, trichosanthin, castanospermine, N-butyl-1-deoxynojirimicin and acemannan.

1 July 2003 in Planta Medica
Verified
Journal Article
Closed access
PDF file
PCPaul Cos
Paul Cos
TBTess De Bruyne
Tess De Bruyne
SASandra Apers
Sandra Apers
DBDirk Vanden Berghe
Dirk Vanden Berghe
LPLuc Pieters
Luc Pieters
AVArnold J. Vlietinck
Arnold J. Vlietinck
Phytoestrogens are polyphenolic non-steroidal plant compounds with estrogen-like biological activity. Based on their chemical structure, phytoestrogens can be classified into four main groups, i. e., isoflavonoids, flavonoids, stilbenes, and lignans. For each group, the chemistry, dietary sources and biotransformation of the most interesting compounds will be discussed. Since phytoestrogens are structurally very similar to the estrogen 17β-estradiol, they may exhibit selective estrogen receptor modulating activities. Therefore, special attention will be given to the hormonal effects of various isoflavonoids, including genistein, daidzein, coumestrol and equol, several prenylated flavonoids, especially 8-prenylnaringenin, and the stilbene resveratrol. Furthermore, their non-hormonal effects will be discussed briefly. Finally, the latest developments on the potential protective properties of phytoestrogens and phytoestrogen-containing foods against hormone-dependent breast and prostate cancers and cardiovascular diseases, and as estrogen replacement therapy for postmenopausal women will be discussed.

1 July 1997 in Journal of Natural Products
Verified
Journal Article
Closed access
KCKanyanga Cimanga
Kanyanga Cimanga
TBTess De Bruyne
Tess De Bruyne
LPLuc Pieters
Luc Pieters
AVArnold J. Vlietinck
Arnold J. Vlietinck
CTCaesar A. Turger
Caesar A. Turger

1 July 2004 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LTL. Tona
L. Tona
RCR.K. Cimanga
R.K. Cimanga
KMK. Mesia
K. Mesia
CMC.T. Musuamba
C.T. Musuamba
TBTess De Bruyne
Tess De Bruyne
AVA.J. Vlietinck
A.J. Vlietinck